About
Small molecules for metabolic diseases
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
1,224
By Phase
PHASE2: 2PHASE2/PHASE3: 2PHASE1: 4
By Status
COMPLETED: 5RECRUITING: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07145229Lead Sponsor
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
PHASE2Recruiting
380 participants
Started: Aug 26, 2025 · Completed: Jun 30, 2026
NCT06276556Lead Sponsor
Extension Study of ABP-671 in Participants With Gout
PHASE2/PHASE3Terminated
43 participants
Started: Apr 22, 2024 · Completed: Sep 5, 2024
NCT06258213Lead Sponsor
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
PHASE1Completed
90 participants
Started: Jan 23, 2024 · Completed: Jul 29, 2024
NCT05818085Lead Sponsor
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
PHASE2/PHASE3Active, not recruiting
580 participants
Started: Aug 11, 2023 · Completed: Aug 31, 2025
NCT04638543Lead Sponsor
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
PHASE2Completed
60 participants
Started: Nov 27, 2020 · Completed: Oct 26, 2021
Locations (1)
Headquarters
Suzhou, China
Map
Loading map...